TrialScope is part of Informa Pharma Intelligence, a division of Informa Business Intelligence, Inc. (IBI). IBI is a wholly-owned subsidiary of Informa PLC.

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

TrialScope Adds Eisai to Its Community of Study Sponsors


October 1, 2020

Eisai Inc. to Manage Its Clinical Trial Disclosure Using TrialScope Technology

Jersey City, NJ, Oct. 1, 2020 — TrialScope, the global leader in clinical trial disclosure and transparency management technology, has added a new study sponsor to its growing customer roster. Eisai Inc. will manage its global clinical trial disclosure compliance process for upwards of 800 studies using the TrialScope Disclose™ platform.

TrialScope customers include 16 of the top 20 industry sponsors, who rely on its technology for trial disclosure management, patient engagement and study recruitment. Collectively, TrialScope customers are responsible for more than 40 percent of all industry trials on and the EU-CTR.

With clinical trials conducted worldwide, Eisai will take advantage of TrialScope’s Global Registry Compliance module, enabling its Global Clinical Trial Transparency department to stay on top of evolving global regulations. The module’s rules engine tracks and updates over 65 regulations for more than 35 clinical trial registries across 100-plus countries.

TrialScope Disclose functionality includes field-level commenting and review-and-approval workflow functionality. These features, ensuring timely compliance and audit-readiness, will facilitate global collaboration for Eisai’s Global Clinical Trial Transparency department. 

“Clinical trial disclosure regulatory compliance is important to Eisai, and not just because it is mandated legally,” said Neil Yolland, Director, Global Clinical Trial Transparency and Clinical & Business Systems at Eisai. “Clinical trial transparency reflects our corporate philosophy of ‘hhc’ – human health care – viewing everything from the perspective of patients and their families. We disclose trial information because it is the right thing to do, and we are ready to streamline the process with the TrialScope Transparency Cloud.”

“We welcome Eisai to the TrialScope community and admire its commitment to global clinical trial disclosure and transparency,” said TrialScope CEO Jeff Kozloff. “We are eager to help Eisai realize the many efficiencies of our platform in terms of automation and trial data reuse.”

For more information on TrialScope or TrialScope Disclose, visit

About TrialScope 

TrialScope gives your clinical trial data superpowers™. The TrialScope Transparency Cloud™ makes centralizing, structuring and activating clinical trial information simple, for use across the organization and at every stage of the study. Our integrated platform is used by 16 of the top 20 clinical trial sponsors in the world, who rely on TrialScope to ensure disclosure compliance, maximize trial transparency, improve patient engagement and accelerate study recruitment. To learn more, visit

About Eisai Inc.

At Eisai Inc., human health care (hhc) is our goal. We give our first thoughts to patients and their families, and helping to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we have a passionate commitment to patient care that is the driving force behind our efforts to discover and develop innovative therapies to help address unmet medical needs.

Eisai is a fully integrated pharmaceutical business that operates in two global business groups: oncology and neurology (dementia-related diseases and neurodegenerative diseases). Our U.S. headquarters, commercial and clinical development organizations are located in New Jersey; our discovery labs are in Massachusetts and Pennsylvania; and our global demand chain organization resides in Maryland and North Carolina. To learn more, visit and follow us on Twitter and LinkedIn.